2014

IDEXX Laboratories Announces Second Quarter Results

WESTBROOK, Maine, July 20, 2012 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), today reported that revenues for the second quarter of 2012 increased 6% to $335.6 million, from $317.9 million for the second quarter of 2011. Organic revenue growth[1] was 7%. Earnings per diluted share ("EPS") for the quarter ended June 30, 2012 increased 10% to $0.91, compared to $0.83 for the same period in the prior year.

(Logo: http://photos.prnewswire.com/prnh/20110602/NE13041LOGO )

"I am pleased with our second quarter results," stated Jonathan Ayers, Chairman and Chief Executive Officer. "With the first half of the year complete, we remain on track for 8-9% organic revenue growth for full year 2012, based on our continued strategy of innovation that supports our customers' growth and success around the globe."

"In the third quarter, we are introducing two new software offerings that advance our strategy of supporting the veterinarian in communicating the value of pet health to pet owners. The first, Pet Health Network® Pro, is a new client communication and education service for veterinarians, practice managers and their teams that offers an automated set of tools to strengthen the client relationship before, during and after each patient visit. The second, VetConnect® PLUS, is an innovative cloud-based tool that enables veterinarians to see all of a patient's diagnostic history generated from IDEXX in-house analyzers and IDEXX Reference Laboratories on one interactive screen, and share those results with pet owners in a client-friendly way. With easy access to a patient's blood work history, the veterinarian is able to more easily discern important trends and thus make better medical recommendations, while conveying those recommendations to the pet owner in a way that results in higher client compliance and practice growth." 

"I am also pleased to announce some organizational changes that will position us for continued growth.  We have created a new structure consisting of three operating Executive Vice Presidents and a set of key functional staff that will report to the CEO.  The three operating Executive Vice Presidents collectively will have responsibility for essentially all of the Company's global operations, each with direct oversight of a portfolio of lines of business and geographic regions."

"I am pleased that Johnny Powers and Michael Williams, executives with extensive track records of success at IDEXX, have been elevated to two of these Executive Vice President positions.  I am also very pleased to announce the recruitment of Jay Mazelsky for the third Executive Vice President role.  Jay comes from Philips Healthcare, where he was most recently Senior Vice President and General Manager of their global Computed Tomography, Nuclear Medicine and Radiation Therapy Planning businesses.  Jay is a seasoned executive who has extensive experience with product and software innovation in the healthcare field, and will be a great addition to our IDEXX team."

"In connection with these changes we also have promoted Merilee Raines, our Chief Financial Officer, and Bill Brown, our Chief Scientific Officer, to Executive Vice President in recognition of their respective critical roles in the past and future success of IDEXX." 

"I look forward to working closely with this executive team, as well as our broader leadership team, in the years ahead to promote continued growth and innovation at IDEXX."

Revenue Performance

Please refer to the table below entitled "Revenues and Revenue Growth Analysis by Product and Service Categories" in conjunction with the following discussion.

Companion Animal Group. Companion Animal Group ("CAG") revenues for the second quarter of 2012 were $278.3 million compared to $259.7 million for the second quarter of 2011. Organic revenue growth of 8% was due primarily to growth in our instrument and consumables business and in our reference laboratory diagnostic and consulting services business. The revenue increase in our instruments and consumables business was largely the result of higher sales volumes of our Catalyst Dx® and ProCyte Dx® instruments and related consumables. In our reference laboratory diagnostic and consulting services business, revenues increased due to higher sales volumes driven primarily by the acquisition of new customers due, in part, to geographic expansion. Revenue from acquisitions contributed 1% to revenue growth and changes in foreign currency exchange rates reduced revenue growth by 3%.

Water. Water revenues for the second quarter of 2012 were $22.0 million compared to $21.5 million for the second quarter of 2011. Organic revenue growth of 5% was due primarily to higher Colilert® product sales volumes driven by new account acquisitions. Changes in foreign currency exchange rates reduced revenue growth by 3%.

Livestock and Poultry Diagnostics. Livestock and Poultry Diagnostics ("LPD") revenues for the second quarter of 2012 were $23.1 million compared to $25.4 million for the second quarter of 2011. The 4% decline in organic revenue was due primarily to lower sales of Bovine Spongiform Encephalopathy ("BSE" or otherwise commonly referred to as mad cow disease) tests resulting from changes in European Union BSE testing requirements. Effective July 1, 2011, the age at which healthy cattle to be slaughtered are required to be tested for BSE in the European Union was increased from 48 to 72 months, which is reducing the population of cattle tested for this disease. Changes in foreign currency exchange rates reduced revenue growth by 5%.

Additional Operating Results for the Second Quarter

Gross profit for the second quarter of 2012 increased $10.7 million, or 6%, to $184.7 million from $174.0 million for the second quarter of 2011. As a percentage of total revenue, gross profit increased slightly to 55%. The increase in the gross profit percentage was due primarily to the favorable impact of currency as hedging gains more than offset the net unfavorable impact of changes in foreign currency exchange rates.

Selling, general and administrative ("SG&A") expense for the second quarter of 2012 was $88.8 million, or 26% of revenue, compared to $84.1 million, or 26% of revenue, for the second quarter of 2011. The increase in SG&A expense was due primarily to increased personnel-related costs, partly offset by the favorable impact of changes in foreign currency exchange rates. Research and development ("R&D") expense for the second quarter of 2012 was $20.0 million, or 6% of revenue, compared to $18.6 million, or 6% of revenue for the second quarter of 2011. The increase in R&D expense resulted primarily from increased personnel-related costs and higher external consulting and development costs.

Supplementary Analysis of Results

The accompanying financial tables provide more information concerning our revenue and other operating results for the three and six months ended June 30, 2012.

Outlook for 2012

The Company provides the following guidance for the full year of 2012. The guidance reflects an assumption that the value of the U.S. dollar relative to other currencies will remain at our current assumptions of the euro at $1.23, the British pound at $1.53 and the Canadian dollar at $0.97 for the balance of 2012. Based on these assumptions, a 1% strengthening of the U.S. dollar would decrease revenue by approximately $4.5 million and operating profit by approximately $0.8 million on an annual basis. Fluctuations in foreign currency exchange rates from current assumptions could have a significant positive or negative impact on our actual results of operations for 2012.

  • Revenues are expected to be $1.30 to $1.31 billion, which represents reported growth of 7% to 8% and organic growth of 8% to 9%. Organic revenue growth is unchanged from our previous guidance. The decrease in expected reported revenue compared to our previous guidance is due exclusively to unfavorable changes in foreign currency exchange rates, reflecting a strengthening of the U.S. dollar relative to other currencies since the date of our previous guidance.  
  • EPS are expected to be $3.05 to $3.10, compared to our previous guidance of $3.07 to $3.12. The change in EPS guidance is due exclusively to the unfavorable impact of changes in foreign currency exchange rates since the date of our previous guidance.
  • Free cash flow is expected to be 105% to 110% of net income.[2]
  • Capital expenditures are expected to be approximately $60 million.

Conference Call and Webcast Information

IDEXX Laboratories will be hosting a conference call today at 9:00 a.m. (eastern) to discuss its second quarter results and management's outlook. To participate in the conference call, dial 1-612-288-0337 or 1-800-230-1074 and reference confirmation code 254010. An audio replay will be available through July 27, 2012 by dialing 1-320-365-3844 and referencing replay code 254010.

The call will also be available via live or archived webcast on the IDEXX Laboratories' web site at http://www.idexx.com.

About IDEXX Laboratories, Inc.

IDEXX Laboratories, Inc. is a leader in pet healthcare innovation, serving practicing veterinarians around the world with a broad range of diagnostic and information technology-based products and services. IDEXX products enhance the ability of veterinarians to provide advanced medical care, improve staff efficiency and build more economically successful practices. IDEXX is also a worldwide leader in providing diagnostic tests and information for livestock and poultry and tests for the quality and safety of water and milk. Headquartered in Maine, IDEXX Laboratories employs more than 5,000 people and offers products to customers in over 100 countries.

Note Regarding Forward-Looking Statements

This press release contains statements about the Company's business prospects and estimates of the Company's financial results for future periods that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as "expects," "may," "anticipates," "intends," "would," "will," "plans," "believes," "estimates," "should," and similar words and expressions. These statements are based on management's expectations of future events as of the date of this press release, and the Company assumes no obligation to update any forward-looking statements as a result of new information or future events or developments. Actual results could differ materially from management's expectations. Factors that could cause or contribute to such differences include the following: the Company's ability to develop, manufacture, introduce and market new products and enhancements to existing products; the Company's ability to achieve cost improvements in its worldwide network of laboratories and in the manufacture of in-clinic instruments;the Company's ability to identify acquisition opportunities, complete acquisitions and integrate acquired businesses; disruptions, shortages or pricing changes that affect the Company's purchases of products and materials from third parties, including from sole source suppliers; the Company's ability to manufacture complex biologic products; the impact of a weak economy on demand for the Company's products and services; the effectiveness of the Company's sales and marketing activities; the effect of government regulation on the Company's business, including government decisions about whether and when to approve the Company's products and decisions regarding labeling, manufacturing and marketing products; the impact of the resolution of the U.S. Federal Trade Commission investigation into the Company's marketing and sales practices; the impact of a change in the status of one of the Company's distributors on its results of operations;the Company's ability to obtain patent and other intellectual property protection for its products, successfully enforce its intellectual property rights and defend itself against third party claims against the Company; the impact of distributor purchasing decisions on sales of the Company's products that are sold through distribution; the impact of competition, technological change, veterinary hospital consolidation, and the prevalence of buying consortiums on the markets for the Company's products; changes or trends in veterinary medicine that affect the rate of use of the Company's products and services by veterinarians; the impact of the Company's inexperience and small scale in the human point-of-care market; the effects of operations outside the U.S., including  from currency fluctuations, different regulatory, political and economic conditions, and different market conditions; the effects of interruptions to the Company's operations due to natural disasters or system failures; the impact of any class action litigation due to stock price volatility; the effect on the Company's stock price if quarterly or annual operations results do not meet expectations of market analysts or investors in future periods; and potential exposures related to our worldwide provision for income taxes and the potential loss of tax incentives. A further description of these and other factors can be found in the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2012, in the section captioned "Risk Factors."

[1] Organic revenue growth for the second quarter of 2012 excludes revenue from business acquisitions, which contributed 1% to revenue growth, and the impact of changes in foreign currency exchange rates, which reduced revenue growth by 3%.

[2] Free cash flow is a non-U.S. GAAP measure. We calculate free cash flow as cash generated from operations, excluding our royalty prepayment in the first quarter of 2012, and tax benefits attributable to share-based compensation arrangements, reduced by our investments in fixed assets. We feel free cash flow is a useful measure because it indicates the cash the operations of the business are generating after appropriate reinvestment for recurring investments in fixed assets that are required to operate the business. We believe this is a common financial measure useful to further evaluate the results of operations. Refer to our reconciliation below for our calculation of free cash flow. With respect to this particular forward-looking projection, the Company is unable to provide a quantitative reconciliation at this time as the inputs to the measurement are difficult to predict and estimate and are primarily dependent on future events.


IDEXX Laboratories, Inc. and Subsidiaries





Consolidated Statement of Operations





Amounts in thousands except per share data (Unaudited)
















Three Months Ended


Six Months Ended




June 30,

June 30,


June 30,

June 30,




2012

2011


2012

2011

Revenue:

Revenue


$       335,649

$      317,862


$       658,325

$      610,534

Expenses and








Income:

Cost of revenue


150,960

143,829


298,862

281,576


Gross profit


184,689

174,033


359,463

328,958


Sales and marketing


54,539

50,974


112,171

101,959


General and administrative


34,275

33,140


70,453

65,736


Research and development


20,058

18,621


40,615

36,433


Income from operations


75,817

71,298


136,224

124,830


Interest expense, net


446

363


1,203

722


Income before provision for income taxes


75,371

70,935


135,021

124,108


Provision for income taxes


24,051

22,281


42,967

38,848

Net Income:

Net income


51,320

48,654


92,054

85,260


Less: Noncontrolling interest in subsidiary's








earnings (losses)


3

(3)


(6)

(9)


Net income attributable to stockholders


$       51,317

$       48,657


$       92,060

$       85,269


Earnings per share: Basic


$           0.93

$           0.85


$           1.67

$           1.49


Earnings per share: Diluted


$           0.91

$           0.83


$           1.63

$           1.45


Shares outstanding: Basic


55,079

57,276


55,143

57,366


Shares outstanding: Diluted


56,211

58,727


56,345

58,934









IDEXX Laboratories, Inc. and Subsidiaries







Selected Operating Information (Unaudited)


















Three Months Ended


Six Months Ended




June 30,

June 30,


June 30,

June 30,




2012

2011


2012

2011

Operating

Gross profit


55.0%

54.8%


54.6%

53.9%

Ratios (as a

Sales, marketing, general and







percentage of

administrative expense


26.5%

26.5%


27.7%

27.5%

revenue):

Research and development expense


6.0%

5.9%


6.2%

6.0%


Income from operations (1)


22.6%

22.4%


20.7%

20.5%

















International

International revenue (in thousands)


$       135,950

$    137,585


$       268,234

$    260,155

Revenue:

International revenue as percentage








of total revenue


40.5%

43.3%


40.7%

42.6%









(1) Amounts presented may not recalculate due to rounding.


IDEXX Laboratories, Inc. and Subsidiaries





Segment Information





Amounts in thousands (Unaudited)
















Three Months Ended


Three Months Ended




June 30,

Percent of


June 30,

Percent of




2012

Revenue


2011

Revenue

Revenue:

CAG


$       278,294



$        259,734



Water


21,983



21,510



LPD


23,060



25,367



Other


12,312



11,251



Total


$       335,649



$        317,862










Gross Profit:

CAG


$       147,908

53.1%


$        138,332

53.3%


Water


14,794

67.3%


12,968

60.3%


LPD


15,671

68.0%


17,335

68.3%


Other


4,575

37.2%


4,742

42.2%


Unallocated Amounts


1,741

N/A


656

N/A


Total


$       184,689

55.0%


$        174,033

54.8%









Income from








Operations:

CAG


$         59,768

21.5%


$          58,270

22.4%


Water


10,196

46.4%


8,401

39.1%


LPD


5,810

25.2%


7,176

28.3%


Other


250

2.0%


309

2.8%


Unallocated Amounts


(207)

N/A


(2,858)

N/A


Total


$         75,817

22.6%


$          71,298

22.4%









































Six Months Ended


Six Months Ended




June 30,

Percent of


 June 30,

Percent of




2012

Revenue


2011

Revenue

Revenue:

CAG


$       546,367



$        500,323



Water


41,565



40,475



LPD


45,242



49,306



Other


25,151



20,430



Total


$       658,325



$        610,534










Gross Profit:

CAG


$       287,309

52.6%


$        261,683

52.3%


Water


27,761

66.8%


24,359

60.2%


LPD


30,853

68.2%


33,882

68.7%


Other


9,892

39.3%


8,484

41.5%


Unallocated Amounts


3,648

N/A


550

N/A


Total


$       359,463

54.6%


$        328,958

53.9%









Income from








Operations:

CAG


$       106,686

19.5%


$           101,242

20.2%


Water


18,491

44.5%


15,348

37.9%


LPD


11,076

24.5%


14,326

29.1%


Other


788

3.1%


(241)

(1.2%)


Unallocated Amounts


(817)

N/A


(5,845)

N/A


Total


$       136,224

20.7%


$           124,830

20.5%










IDEXX Laboratories, Inc. and Subsidiaries

Revenues and Revenue Growth Analysis by Product and Service Categories

Amounts in thousands (Unaudited)
















Net Revenue

Three
Months
Ended June
30,
2012


Three
Months Ended June 30,
2011


Dollar

Change


Percentage

Change


Percentage

Change from

Currency (1)


Percentage
Change
from
Acquisitions (2)


Organic
Revenue Growth
(3)




















CAG

$

278,294


$

259,734


$

18,560


7.1%


(2.5%)


1.4%


8.2%


Water


21,983



21,510



473


2.2%


(2.5%)


-


4.7%


LPD


23,060



25,367



(2,307)


(9.1%)


(5.3%)


-


(3.8%)


Other


12,312



11,251



1,061


9.4%


(1.5%)


-


10.9%


Total

$

335,649


$

317,862


$

17,787


5.6%


(2.6%)


1.1%


7.1%






































Net CAG Revenue

Three
Months
Ended June
30, 2012


Three
Months Ended June 30, 2011


Dollar

Change


Percentage

Change


Percentage

Change from

Currency (1)


Percentage

Change from

Acquisitions (2)


Organic Revenue Growth(3)


















Instruments and consumables

$

104,243


$

98,603


$

5,640


5.7%


(2.8%)


-


8.5%

Rapid assay products


45,577



44,193



1,384


3.1%


(1.1%)


-


4.2%

Reference laboratory diagnostic and consulting services


106,385



99,087



7,298


7.4%


(3.0%)


3.6%


6.8%

Practice management and digital imaging systems


22,089



17,851



4,238


23.7%


(0.4%)


-


24.1%

Net CAG revenue

$

278,294


$

259,734


$

18,560


7.1%


(2.5%)


1.4%


8.2%



































(1) The percentage change from currency is a non-U.S. GAAP measure. It represents the percentage change in revenue resulting from the difference between the average exchange rates during the three months ended June 30, 2012 and the same period of the prior year applied to foreign currency denominated revenues for the three months ended June 30, 2012.

(2) The percentage change from acquisitions is a non-U.S. GAAP measure. It represents the percentage change in revenue during the three months ended June 30, 2012 compared to the three months ended June 30, 2011 attributed to acquisitions subsequent to March 31, 2011.

(3) Organic revenue growth is a non-U.S. GAAP measure and represents the percentage change in revenue during the three months ended June 30, 2012 compared to the three months ended June 30, 2011 net of acquisitions and the effect of changes in foreign currency exchange rates.

 

IDEXX Laboratories, Inc. and Subsidiaries

Revenues and Revenue Growth Analysis by Product and Service Categories

Amounts in thousands (Unaudited)
















Net Revenue

Six Months Ended June 30, 2012


Six Months Ended June 30, 2011


Dollar

Change


Percentage

Change


Percentage

Change from

Currency (1)


Percentage

Change from

Acquisitions (2)


Organic
Revenue Growth
(3)




















CAG

$

546,367


$

500,323


$

46,044


9.2%


(1.5%)


1.4%


9.3%


Water


41,565



40,475



1,090


2.7%


(1.5%)


-


4.2%


LPD


45,242



49,306



(4,064)


(8.2%)


(3.5%)


-


(4.7%)


Other


25,151



20,430



4,721


23.1%


(0.5%)


-


23.6%


Total

$

658,325


$

610,534


$

47,791


7.8%


(1.7%)


1.2%


8.3%






































Net CAG Revenue

Six Months Ended June 30, 2012


Six Months Ended June 30, 2011


Dollar

Change


Percentage

Change


Percentage

Change from

Currency (1)


Percentage

Change from

Acquisitions (2)


Organic
Revenue Growth
(3)




















Instruments and consumables

$

206,240


$

192,490


$

13,750


7.1%


(1.7%)


-


8.8%


Rapid assay products


89,241



82,810



6,431


7.8%


(0.6%)


-


8.4%


Reference laboratory diagnostic and consulting   services


208,247



188,215



20,032


10.6%


(1.9%)


3.8%


8.7%


Practice management and  digital imaging systems


42,639



36,808



5,831


15.8%


(0.2%)


-


16.0%


Net CAG revenue

$

546,367


$

500,323


$

46,044


9.2%


(1.5%)


1.4%


9.3%



















(1) The percentage change from currency is a non-U.S. GAAP measure. It represents the percentage change in revenue resulting from the difference between the average exchange rates during the six months ended June 30, 2012 and the same period of the prior year applied to foreign currency denominated revenues for the six months ended June 30, 2012.

(2) The percentage change from acquisitions is a non-U.S. GAAP measure. It represents the percentage change in revenue during the six months ended June 30, 2012 compared to the six months ended June 30, 2011 attributed to acquisitions subsequent to December 31, 2010.

(3) Organic revenue growth is a non-U.S. GAAP measure and represents the percentage change in revenue during the six months ended June 30, 2012 compared to the six months ended June 30, 2011 net of acquisitions and the effect of changes in foreign currency exchange rates.


IDEXX Laboratories, Inc. and Subsidiaries


Consolidated Balance Sheet


Amounts in thousands (Unaudited)
















June 30,

December 31,







2012

2011

Assets:

Current Assets:








Cash and cash equivalents





$           201,813

$          183,895


Accounts receivable, net





147,159

141,275


Inventories





143,703

133,099


Other current assets





62,632

65,958


Total current assets





555,307

524,227


Property and equipment, net





220,580

216,777


Other long-term assets, net





291,430

289,810


Total assets





$       1,067,317

$       1,030,814

Liabilities and








Stockholders'








Equity:

Current Liabilities:








Accounts payable





$            29,706

$            36,551


Accrued liabilities





128,478

141,383


Debt





244,945

243,917


Deferred revenue





16,022

15,028


Total current liabilities





419,151

436,879


Long-term debt, net of current portion





2,021

2,501


Other long-term liabilities





56,204

51,841


Total long-term liabilities





58,225

54,342










Total stockholders' equity





589,933

539,579


Noncontrolling interest





8

14


Total equity





589,941

539,593


Total liabilities and stockholders' equity





$        1,067,317

$        1,030,814


























IDEXX Laboratories, Inc. and Subsidiaries






Selected Balance Sheet Information (Unaudited)
















June 30,


March 31,

December 31,


September 30,

June 30,



2012


2012

2011


2011

2011

Selected                  









Balance Sheet

Days sales outstanding (1)

41.9


42.7

41.0


43.1

41.2

Information:

Inventory turns (2)

1.8


1.8

1.8


1.7

1.7










(1)  Days sales outstanding represents the average of the accounts receivable balances at the beginning and end of each quarter divided by revenue
       for that quarter, the result of which is then multiplied by 91.25 days.

(2)  Inventory turns represents inventory-related cost of product sales for the 12 months preceding each quarter-end divided by the inventory balance
       at the end of the quarter.


IDEXX Laboratories, Inc. and Subsidiaries




Consolidated Statement of Cash Flows




Amounts in thousands (Unaudited)












Six Months Ended




June 30,

June 30,




2012

2011

Operating:

Cash Flows from Operating Activities:





Net income


$         92,054

$      85,260


Non-cash charges


32,458

34,316


Changes in assets and liabilities


(39,766)

(20,412)


Tax benefit from share-based compensation arrangements


(5,946)

(10,854)


Net cash provided by operating activities


78,800

88,310

Investing:

Cash Flows from Investing Activities:





Purchases of property and equipment


(24,301)

(26,173)


Proceeds from disposition of pharmaceutical product lines


3,000

3,000


Proceeds from sale of property and equipment


45

218


Acquisition of intangible asset


(900)

-


Net cash used by investing activities


(22,156)

(22,955)

Financing:

Cash Flows from Financing Activities:





Borrowings on revolving credit facilities, net


1,000

3,486


Payment of notes payable


(452)

(425)


Repurchases of common stock


(55,006)

(98,419)


Proceeds from the exercise of stock options and employee stock purchase plans


10,247

19,367


Tax benefit from share-based compensation arrangements


5,946

10,854


Net cash used by financing activities


(38,265)

(65,137)


Net effect of changes in exchange rates on cash


(461)

2,265


Net increase in cash and cash equivalents


17,918

2,483


Cash and cash equivalents, beginning of period


183,895

156,915


Cash and cash equivalents, end of period


$          201,813

$     159,398

















IDEXX Laboratories, Inc. and Subsidiaries




Free Cash Flow




Amounts in thousands (Unaudited)










Six Months Ended







June 30,

June 30,







2012

2011

Free Cash





Flow:

Net cash provided by operating activities


78,800

88,310


Royalty prepayment to obtain exclusive patent rights


6,250

-


Financing cash flows attributable to tax benefits from share-based compensation arrangements


5,946

10,854


Purchases of property and equipment


(24,301)

(26,173)


Free cash flow


66,695

72,991



















 

IDEXX Laboratories, Inc. and Subsidiaries


Common Stock Repurchases


Amounts in thousands except per share data (Unaudited)








Three Months Ended


Six Months Ended




June 30,

June 30,


June 30,

June 30,




2012

2011


2012

2011


Share repurchases during the period


319

759


652

1,297


Average price paid per share


$            85.84

$           77.08


$           84.32

$           75.89










Shares remaining under repurchase authorization as of June 30, 2012 totaled 3,735,326.                                 







Share repurchases do not include shares surrendered by employees in payment for the minimum required
withholding taxes due on the vesting of restricted stock units and the settlement of deferred stock units.


Contact: Merilee Raines, Chief Financial Officer, 1-207-556-8155

SOURCE IDEXX Laboratories, Inc.



RELATED LINKS
http://www.idexx.com

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.